NCT02780401View on ClinicalTrials.gov

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 2, 2016

Primary Completion Date

October 8, 2020

Study Completion Date

October 8, 2022

Conditions
HER2/Neu NegativeNo Evidence of DiseaseOne or More Positive Axillary NodesStage IB Breast CancerStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

Given ID

BIOLOGICAL

Sargramostim

Given ID

Trial Locations (2)

53792

University of Wisconsin Hospital and Clinics, Madison

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Wisconsin, Madison

OTHER

lead

University of Washington

OTHER

NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission | Biotech Hunter | Biotech Hunter